These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25212753)

  • 1. What is the future of pediatric liver transplantation? Optimal management of long-term recipients.
    Venick RS
    Liver Transpl; 2014 Nov; 20 Suppl 2():S19-21. PubMed ID: 25212753
    [No Abstract]   [Full Text] [Related]  

  • 2. The impact of early corticosteroid withdrawal on graft survival in liver transplant recipients.
    Meadows HB; Taber DJ; Pilch NA; Tischer SM; Baliga PK; Chavin KD
    Transplant Proc; 2012 Jun; 44(5):1323-8. PubMed ID: 22664009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What do we know about the clinical impact of complete withdrawal of immunosuppression in liver transplantation?
    Pons JA; Revilla Nuin B; Ramírez P; Baroja Mazo A; Martínez Alarcón L; Robles R; Sánchez Bueno F; Rios A; Cascales Campos P; Parrilla P
    Transplant Proc; 2012; 44(6):1530-2. PubMed ID: 22841204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Operational tolerance: past lessons and future prospects.
    Levitsky J
    Liver Transpl; 2011 Mar; 17(3):222-32. PubMed ID: 21384504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CNIs: immediate benefits but storing problems for the future?
    Kiuchi T
    Transplantation; 2008 Oct; 86(8):1026-7. PubMed ID: 18946338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there such a thing as protocol immunosuppression in liver transplantation?
    McCaughan GW; Sze KC; Strasser SI
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):1-4. PubMed ID: 25164689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression Practices in Liver Transplantation: A Survey of North American Centers.
    Hussaini T; Turgeon RD; Partovi N; Erb SR; Scudamore CH; Yoshida EM
    Exp Clin Transplant; 2018 Oct; 16(5):550-553. PubMed ID: 28847263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends of Immunosuppression and Outcomes Following Liver Transplantation: An Analysis of the United Network for Organ Sharing Registry.
    Cheng EY; Everly MJ
    Clin Transpl; 2014; ():13-26. PubMed ID: 26281123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic vs. concentration-controlled optimization of tacrolimus dosing in renal allograft recipients.
    Kuypers DR
    Clin Pharmacol Ther; 2010 Nov; 88(5):595-6; author reply 597. PubMed ID: 20664539
    [No Abstract]   [Full Text] [Related]  

  • 10. Longterm Survival and Cost-Effectiveness of Immunosuppression Withdrawal After Liver Transplantation.
    Manzia TM; Angelico R; Toti L; Angelico C; Quaranta C; Parente A; Blasi F; Iesari S; Sforza D; Baiocchi L; Lerut J; Tisone G
    Liver Transpl; 2018 Sep; 24(9):1199-1208. PubMed ID: 30129171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Living-donor liver transplantation at the University of Tokyo, 1996-2011: the impact of HLA matching and a positive crossmatch on long-term survival and tolerance.
    Waki K; Sugawara Y; Mizuta K; Fujita H; Kadowaki T; Kokudo N
    Clin Transpl; 2011; ():223-35. PubMed ID: 22755416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppression with budesonide for liver transplant recipients with severe infections.
    Bhat M; Ghali P; Wong P; Marcus V; Michel R; Cantarovich M; Metrakos P; Deschenes M
    Liver Transpl; 2012 Feb; 18(2):262-3. PubMed ID: 22006869
    [No Abstract]   [Full Text] [Related]  

  • 13. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients.
    Charlton M; Levitsky J; Aqel B; OʼGrady J; Hemibach J; Rinella M; Fung J; Ghabril M; Thomason R; Burra P; Little EC; Berenguer M; Shaked A; Trotter J; Roberts J; Rodriguez-Davalos M; Rela M; Pomfret E; Heyrend C; Gallegos-Orozco J; Saliba F
    Transplantation; 2018 May; 102(5):727-743. PubMed ID: 29485508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential catalysts in therapeutics.
    Luxon BA
    Liver Transpl; 2014 Nov; 20 Suppl 2():S22-31. PubMed ID: 25164576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab and liver transplantation: a review.
    Dhesi S; Boland B; Colquhoun S
    Curr Opin Organ Transplant; 2009 Jun; 14(3):245-9. PubMed ID: 19417659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term management of immunosuppression after pediatric liver transplantation: is minimization or withdrawal desirable or possible or both?
    Feng S
    Curr Opin Organ Transplant; 2008 Oct; 13(5):506-12. PubMed ID: 19060534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients.
    Khanmoradi K; Knorr JP; Feyssa EL; Parsikia A; Jawa P; Dinh DB; Campos S; Zaki RF; Ortiz JA
    Exp Clin Transplant; 2013 Jun; 11(3):222-8. PubMed ID: 23432665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in pediatric solid-organ transplantation.
    LaRosa C; Baluarte HJ; Meyers KE
    Pediatr Transplant; 2011 Mar; 15(2):128-41. PubMed ID: 21309962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The challenge of preserving renal function after liver transplantation.
    Jacquet A; Francois H; Beaudreuil S; Hebibi H; Seidowsky A; Ahmad L; Charpentier B; Durrbach A
    Panminerva Med; 2009 Dec; 51(4):249-55. PubMed ID: 20195235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunosuppression in pediatric liver transplant recipients: Unique aspects.
    Miloh T; Barton A; Wheeler J; Pham Y; Hewitt W; Keegan T; Sanchez C; Bulut P; Goss J
    Liver Transpl; 2017 Feb; 23(2):244-256. PubMed ID: 27874250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.